FR21C1059I2 - PHARMACEUTICAL COMPOSITIONS - Google Patents

PHARMACEUTICAL COMPOSITIONS

Info

Publication number
FR21C1059I2
FR21C1059I2 FR21C1059C FR21C1059C FR21C1059I2 FR 21C1059 I2 FR21C1059 I2 FR 21C1059I2 FR 21C1059 C FR21C1059 C FR 21C1059C FR 21C1059 C FR21C1059 C FR 21C1059C FR 21C1059 I2 FR21C1059 I2 FR 21C1059I2
Authority
FR
France
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1059C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of FR21C1059I1 publication Critical patent/FR21C1059I1/en
Application granted granted Critical
Publication of FR21C1059I2 publication Critical patent/FR21C1059I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR21C1059C 2013-03-15 2021-12-14 PHARMACEUTICAL COMPOSITIONS Active FR21C1059I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792440P 2013-03-15 2013-03-15
PCT/US2014/029421 WO2014144842A2 (en) 2013-03-15 2014-03-14 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
FR21C1059I1 FR21C1059I1 (en) 2022-01-21
FR21C1059I2 true FR21C1059I2 (en) 2022-12-02

Family

ID=50732290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1059C Active FR21C1059I2 (en) 2013-03-15 2021-12-14 PHARMACEUTICAL COMPOSITIONS

Country Status (19)

Country Link
US (2) US11129869B2 (en)
EP (2) EP3778623A1 (en)
JP (3) JP6538025B2 (en)
KR (1) KR102378943B1 (en)
CN (3) CN115957296A (en)
AU (4) AU2014228460B2 (en)
BR (1) BR112015023409B1 (en)
CA (2) CA2906782C (en)
DK (1) DK2970389T3 (en)
ES (1) ES2825076T3 (en)
FR (1) FR21C1059I2 (en)
HK (1) HK1220702A1 (en)
IL (2) IL241378B (en)
NL (1) NL301149I2 (en)
NO (1) NO2021051I1 (en)
PL (1) PL2970389T3 (en)
PT (1) PT2970389T (en)
RU (2) RU2690377C2 (en)
WO (1) WO2014144842A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3539551T1 (en) 2011-12-29 2022-02-28 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
AU2014228460B2 (en) 2013-03-15 2018-11-01 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US10196425B2 (en) * 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
JP2016518358A (en) * 2013-04-11 2016-06-23 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ Polyplex
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016330773A1 (en) * 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
JP6701572B2 (en) * 2016-07-05 2020-05-27 株式会社リコー Ink, container, image forming method, and image forming apparatus
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
MA49883A (en) 2017-03-15 2021-04-21 Novo Nordisk As BICYCLIC COMPOUNDS SUITABLE TO BIND TO MELANOCORTIN 4 RECEPTOR
KR102665710B1 (en) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 GLP-1 composition and its uses
CN112188898A (en) * 2017-11-15 2021-01-05 节奏制药公司 Sustained release peptide formulations
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
KR102087634B1 (en) * 2018-10-11 2020-03-11 (주)바이텍 Composition for anti-obesity
WO2020142102A1 (en) * 2019-01-04 2020-07-09 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As Glp-1 compositions and uses thereof
CN111718408A (en) * 2020-07-06 2020-09-29 成都圣诺生物制药有限公司 Preparation method of Setmelanotide
JP2024532294A (en) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン MC4R agonist peptides
KR20230065921A (en) * 2021-11-05 2023-05-12 (주)아이엠디팜 Novel sustained-release lipid pre-concentrate and sustained-release injectable pharmaceutical composition comprising the same
WO2023247999A1 (en) * 2022-06-24 2023-12-28 Mainline Biosciences (Shanghai) Co., Ltd. Peptidic pain modulators and methods for producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
WO1994026251A1 (en) * 1993-05-07 1994-11-24 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
JP2005504715A (en) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド Inhalable particles with sustained release characteristics
JP2004534851A (en) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． Linear and cyclic peptides specific for the melanocortin receptor
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
FR2851563B1 (en) 2003-02-26 2005-04-22 Sod Conseils Rech Applic NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
FR2852957B1 (en) 2003-03-31 2005-06-10 Sod Conseils Rech Applic NOVEL IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
MXPA05013951A (en) * 2003-06-19 2006-02-24 Lilly Co Eli Melanocortin recptor 4(mc4) agonists and their uses.
FR2862971B1 (en) 2003-11-28 2006-03-24 Sod Conseils Rech Applic NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT
KR100638041B1 (en) 2003-12-24 2006-10-23 주식회사 삼양사 A nanoparticle composition of a water-soluble drug for oral administration and a preparation method thereof
FR2872165B1 (en) 2004-06-24 2006-09-22 Sod Conseils Rech Applic NEW PYRIMIDO-BENZIMIDAZOLE DERIVATIVES
JP2009500426A (en) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Melanocortin receptor ligand
KR101232201B1 (en) 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 Melanocortin receptor ligands
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
AR066175A1 (en) 2007-06-15 2009-08-05 Sod Conseils Rech Applic LEGANDS OF THE RECEPTOR OF MELANOCORTINA OF CYCLIC PEPTIDES
AU2008325194B2 (en) 2007-11-05 2012-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use melanocortins to treat insulin sensitivity
AR072072A1 (en) * 2008-06-09 2010-08-04 Palatin Technologies Inc SPECIFIC PEPTIDES OF THE MELANOCORTINE RECEPTOR FOR THE TREATMENT OF OBESITY / 669
MX2011000036A (en) * 2008-06-25 2011-02-22 Endo Pharmaceuticals Solutions Octreotide implant having a release agent.
CN101439182B (en) 2008-12-18 2012-02-01 北京大学 Somatostatin receptor mediated tumor-targeted medicament composition
MX2011013117A (en) 2009-06-08 2012-05-23 Palatin Technologies Inc Melanocortin receptor-specific peptides.
UY32690A (en) * 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
IN2012DN01493A (en) 2009-08-05 2015-06-05 Ipsen Pharma Sas
WO2011060352A1 (en) 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
US9415012B2 (en) 2011-06-14 2016-08-16 Ipsen Pharma S.A.S. Sustained-release composition containing peptides as active ingredient
JP2013046596A (en) 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd New complex, medicine including the same and method of treatment for cancer
WO2013033838A1 (en) * 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AU2014228460B2 (en) * 2013-03-15 2018-11-01 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
US10196425B2 (en) * 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions

Also Published As

Publication number Publication date
JP2016516062A (en) 2016-06-02
US20220160818A1 (en) 2022-05-26
WO2014144842A3 (en) 2015-04-09
EP3778623A1 (en) 2021-02-17
CN105518021A (en) 2016-04-20
BR112015023409B1 (en) 2023-11-28
AU2014228460B2 (en) 2018-11-01
US20160022764A1 (en) 2016-01-28
CA2906782A1 (en) 2014-09-18
HK1220702A1 (en) 2017-05-12
RU2015143965A (en) 2017-04-24
ES2825076T3 (en) 2021-05-14
IL241378B (en) 2022-01-01
EP2970389B1 (en) 2020-08-19
RU2690377C2 (en) 2019-06-03
BR112015023409A2 (en) 2017-07-18
FR21C1059I1 (en) 2022-01-21
AU2019200101A1 (en) 2019-01-31
PL2970389T3 (en) 2021-03-08
CN115957296A (en) 2023-04-14
CN115957297A (en) 2023-04-14
WO2014144842A2 (en) 2014-09-18
PT2970389T (en) 2020-10-21
JP6538025B2 (en) 2019-07-03
NL301149I1 (en) 2021-12-08
AU2019200101B2 (en) 2021-02-04
JP2019189619A (en) 2019-10-31
IL288961A (en) 2022-02-01
KR20160020405A (en) 2016-02-23
US11129869B2 (en) 2021-09-28
DK2970389T3 (en) 2020-10-26
AU2014228460A1 (en) 2015-10-01
IL241378A0 (en) 2015-11-30
EP2970389A2 (en) 2016-01-20
NL301149I2 (en) 2022-11-24
AU2021202699A1 (en) 2021-05-27
CA3209602A1 (en) 2014-09-18
AU2023204625A1 (en) 2023-08-03
KR102378943B1 (en) 2022-03-25
JP2022065117A (en) 2022-04-26
RU2019116003A (en) 2019-07-17
BR112015023409A8 (en) 2019-12-03
CA2906782C (en) 2023-10-03
NO2021051I1 (en) 2024-08-05

Similar Documents

Publication Publication Date Title
FR21C1059I2 (en) PHARMACEUTICAL COMPOSITIONS
DK3030262T3 (en) COMBINED PHARMACEUTICAL COMPOSITION
DK3089741T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING AZD9291
PL2943181T3 (en) Pharmaceutical compositions
DK2943549T3 (en) SYNERGISTIC H2S-SCAVENGER COMPOSITION
DK3079666T3 (en) Pharmaceutical compositions comprising dimethyl fumarate
DK2968214T3 (en) Unknown analgesic compositions
BR112016010669A2 (en) disinfectant composition
DK3043778T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING REFAMETINIB
ZA201408333B (en) Pharmaceutical compositions
DK3027750T3 (en) BIOKATALYTICAL COMPOSITION
DK2897594T3 (en) PHARMACEUTICAL COMPOSITION
DK3079655T3 (en) INHALABLE MEDICINAL PRODUCTS
FR3001392B1 (en) IMPROVED DERMATOLOGICAL COMPOSITION
DK3079667T3 (en) PHARMACEUTICAL DOSAGE FORMS
DK3003401T3 (en) PHARMACEUTICAL PREPARATION
HRP20171888T1 (en) Pharmaceutical compositions
DK3060213T3 (en) Pharmaceutical compositions comprising antibacterial agents
GB201304699D0 (en) Pharmaceutical compositions
MA42111A (en) TOPICAL PHARMACEUTICAL COMPOSITIONS
TH1401004646B (en) Oral pharmaceutical ingredients
DK3082855T3 (en) COMPOSITION
TH1401004645B (en) Pharmaceutical composition that can be given orally.
TH1401006504A (en) Delayed release drug formulation
TH1501000622A (en) shampoo composition